Találati lista | Tudóstér

001-es BibID:	BIBFORM075566
Első szerző:	Nagy Gábor (laboratóriumi szakorvos, laboratóriumi hematológus és immunológus)
Cím:	Monitoring of drug level and anti-drug antibody production during vedolizumab therapy in patients with inflammatory bowel disease / G. Nagy, É. Török, K. Palatka, Z. Kébel, P. Antal-Szalmás
Dátum:	2018
Megjegyzések:	Integrin ?4?7 is expressed on gut-specific lymphocytes and plays a pivotal role in their migration to the intestine. Vedolizumab (VDZ, trade name Entyvio), a humanized monoclonal IgG1 antibody to the ?4?7 integrin blocks their adhesion to the gut vascular endothelium. In 2014 Entyvio was approved for patients with ulcerative colitis (UC) and Crohn's disease (CD) in Hungary. Our aim was to find and evaluate laboratory tests capable of measuring vedolizumab and anti-vedolizumab antibody (AVA) levels. After overviewing the available methods, LISA-TRACKER Duo Vedolizumab ELISA kit (ref: LTV 005, TheraDiag, Croissy-Beaubourg, France) was chosen. Seventeen samples of 15 patients (9 UC/6 CD) were analyzed. Mean VDZ levels were 18.2 ?g/mL and 7.4 ?g/mL in patients with UC and CD, respectively (p=0.242). Drug levels were significantly higher in patients on concomitant immune modulating therapy (16.9 ?g/mL vs 3.9 ?g/mL, p=0.033). There was no significant correlation between drug concentrations and CRP or disease activity scores. Anti-vedolizumab antibody was not detected in any of the patients (0/15) in accordance with the approximately 4% AVA positivity reported in vedolizumab immunogenicity studies (p=0.430). Five patients had drug levels under the measuring range of the test (<2 ?g/mL) suggesting the possibility of having low affinity anti-drug antibodies not detected by the bridging ELISA method used. In conclusion, LISA-TRACKER Duo Vedolizumab ELISA kit seems to be appropriate to monitor drug and anti-drug antibody levels in patients with inflammatory bowel disease. However, insensitivity of the ELISA methods for detecting low affinity anti-drug antibody may limit its use to determine immunogenicity of vedolizumab.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idézhető absztrakt
Megjelenés:	Clinical Chemistry and Laboratory Medicine. - 56 : 9 (2018), p. eA162. -
További szerzők:	Török Éva Palatka Károly (1961-) (belgyógyász, gasztroenterológus) Kébel Z. Antal-Szalmás Péter (1968-) (laboratóriumi szakorvos)
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon:

001-es BibID:	BIBFORM006783
Első szerző:	Papp Mária (belgyógyász, gasztroenterológus)
Cím:	Haptoglobin polymorphism : a novel genetic risk factor for celiac disease development and its clinical manifestations / Papp, M., Foldi, I., Nemes, E., Udvardy, M., Harsfalvi, J., Altorjay, I., Mate, I., Dinya, T., Varvolgyi, C., Barta, Z., Veres, G., Lakatos, P. L., Tumpek, J., Toth, L., Szathmari, E., Kapitany, A., Gyetvai, A., Korponay-Szabo, I. R.
Dátum:	2008
ISSN:	0009-9147
Megjegyzések:	Haptoglobin (Hp) alpha-chain alleles 1 and 2 account for 3 phenotypes that may influence the course of inflammatory diseases via biologically important differences in their antioxidant, scavenging, and immunomodulatory properties. Hp1-1 genotype results in the production of small dimeric, Hp2-1 linear, and Hp2-2 cyclic polymeric haptoglobin molecules. We investigated the haptoglobin polymorphism in patients with celiac disease and its possible association to the presenting symptoms. METHODS: We studied 712 unrelated, biopsy-proven Hungarian celiac patients (357 children, 355 adults; severe malabsorption 32.9%, minor gastrointestinal symptoms 22.8%, iron deficiency anemia 9.4%, dermatitis herpetiformis 15.6%, silent disease 7.2%, other 12.1%) and 384 healthy subjects. We determined haptoglobin phenotypes by gel electrophoresis and assigned corresponding genotypes. RESULTS: Hp2-1 was associated with a significant risk for celiac disease (P = 0.0006, odds ratio [OR] 1.54, 95% CI 1.20-1.98; prevalence 56.9% in patients vs 46.1% in controls). It was also overrepresented among patients with mild symptoms (69.2%) or silent disease (72.5%). Hp2-2 was less frequent in patients than in controls (P = 0.0023), but patients having this phenotype were at an increased risk for severe malabsorption (OR 2.21, 95% CI 1.60-3.07) and accounted for 45.3% of all malabsorption cases. Celiac and dermatitis herpetiformis patients showed similar haptoglobin phenotype distributions. CONCLUSIONS: The haptoglobin polymorphism is associated with susceptibility to celiac disease and its clinical presentations. The predominant genotype in the celiac population was Hp2-1, but Hp2-2 predisposed to a more severe clinical course. The phenotype-dependent effect of haptoglobin may result from the molecule's structural and functional properties.
Tárgyszavak:	Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban egyetemen (Magyarországon) készült közlemény
Megjelenés:	Clinical Chemistry. - 54 : 4 (2008), p. 697-704. -
További szerzők:	Földi Ildikó (1981-) (orvos) Nemes Éva (1957-) (csecsemő- és gyermekgyógyász, gasztroenterológus) Udvardy Miklós (1947-) (belgyógyász, haematológus) Hársfalvi Jolán (1949-) (klinikai biokémikus) Altorjay István (1954-) (belgyógyász, gasztroenterológus, onkológus) Máté István Dinya Tamás (1974-) (sebész szakorvos, onkológus szakorvos) Várvölgyi Csaba (1958-) (belgyógyász, gasztroenterológus) Barta Zsolt (1964-) (belgyógyász, gasztroenterológus) Veres Gábor (1969-2020) (csecsemő- és gyermekgyógyász, gasztroenterológus) Lakatos Péter (Semmelweis Egyetem) Tumpek Judit (1944-) (orvosi laboratóriumi szakorvos) Tóth László (1971-) (patológus) Szathmári Erzsébet Kapitány Anikó (1979-) (molekuláris biológus) Gyetvai Ágnes Korponay-Szabó Ilma (1959-) (gyermekgyógyász)
Internet cím:	elektronikus változat DOI elektronikus változat
Borító:
Saját polcon: